Other News To Note
Friday, July 20, 2012
Ligand Pharmaceuticals Inc., of San Diego, said partner Pfizer Inc., of New York, reported that the European Medicines Agency accepted for review the marketing authorization application for bazedoxifene/conjugated estrogens (BZA/CE), under review for use in postmenopausal women with a uterus for treating estrogen deficiency symptoms and treating osteoporosis in women at risk of fracture. Pfizer expects a decision in 2013.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.